




IMPORTANT
CONSIDERATIONS
ON HF RISK
FACTORS & HF
PRESENTATION IN
WOMEN

IMPORTANT CONSIDERATIONS ON HF RISK FACTORS & HF PRESENTATION IN WOMEN







Symptoms and/or signs of HF caused by a structural and/or functional cardiac abnormality


CORROBORATED BY AT LEAST ONE OF THE FOLLOWING

Elevated natriuretic peptide levels

Objective evidence of cardiogenic pulmonary or systemic congestion



IMPORTANT CONSIDERATIONS ON HE RISK FACTORS & HE PRESENTATION IN WOMEN



DEFINITION

HF is a clinical syndrome with current or prior

• Symptoms and or signs caused by a structural and/or functional cardiac

And corroborated by at least one of the following:

- Elevated natriuretic peptide levels
- Objective evidence of cardiogenic pulmonary or systemic congestion

STAGES

AT RISK (STAGE A)

Patients at risk for HF, but without current or prior symptoms or signs of HF and without structural cardiac changes or elevated biomarkers of heart disease

PRE-HF (STAGE B)

Patients without current or prior symptoms or signs of HF with evidence of one of the following:

- Structural Heart Disease
- Abnormal cardiac function
- Elevated natriuretic peptide or cardiac troponin levels

HF (STAGE C)

Patients with current or prior symptoms and/or signs of HF caused by a structural and/or functional cardiac abnormality

ADVANCED HF (STAGE D)

Severe symptoms and/or signs of HF at rest, recurrent hospitalizations despite GDMT, refractory or intolerant to GDMT, requiring advanced therapies transplantation, mechanical circulatory support, or palliative care

Language matters!

of Heart

Failure (HF)

The new universal definition offers opportunities for more precise communication and description with terms including **persistent HF** instead of "stable HF," and **HF in remission** rather than "recovered HE."

CLASSIFICATION BY EF

HF with reduced EF (HFrEF)

• HF with LVEF < 40%

HF with mildly reduced EF (HFmrEF)

• HF with LVEF 41-49%

HF with preserved EF (HFpEF)

• HF with LVEF > 50%

HF with improved EF (HFimpEF)

 HF with a baseline LVEF of < 40%, a 10-point increase from baseline LVEF, and a second measurement of LVEF of > 40%



IMPORTANT CONSIDERATIONS ON HF RISK FACTORS & HF PRESENTATION IN WOMEN

PREDISPOSITION

TRADITIONAL RISK FACTORS



Diabetes Mellitus
Hypertension
Obesity
Tobacco Use
Lifestyle
Social
Determinants of
Health



Sex Differences

Risk Factors for Heart Failure

HYPERTENSION

MORE POTENT RISK FACTOR FOR HEART FAILURE IN WOMEN

3X vs 2X

DIABETES

MORE POTENT RISK FACTOR FOR HEART FAILURE IN WOMEN

5X vs 2X

OBESITY

HIGHER RISK FOR HEART FAILURE IN WOMEN STRONGER RISK FACTOR FOR HFPEF

SMOKING

MORE POTENT RISK FACTOR FOR HEART FAILURE IN WOMEN VS MEN



PREDISPOSITION

SEX-SPECIFIC RISK FACTORS

BREAST CANCER THERAPY

- Anthracycline/tyrosine kinase inhibitor-associated LV dysfunction (potentiated risk if both)
- Radiation

Sex-Specific Risk Factors In Women

AUTOIMMUNE DISEASE

- ↑ Prevalence of SLE, RA, scleroderma in women
- ↑ Inflammation
- † Innate immunity

PREGNANCY

Gestational HT, DM,

- Preeclampsia
- Eclampsia
- Peripartum cardiomyopathy

ACUTE CORONARY SYNDROME W/O CAD

Stress Cardiomyopathy

- Emotional > physical triggers
- Apical ballooning & LV dysfunction

Spontaneous Coronary Artery Dissection (?)



SEX DIFFERENCES IN HF

PRESENTATION & PROGNOSIS

